Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells
Sandra Handgraaf, … , Jacques Philippe, Yvan Gosmain
Sandra Handgraaf, … , Jacques Philippe, Yvan Gosmain
Published April 5, 2018
Citation Information: JCI Insight. 2018;3(7):e98569. https://doi.org/10.1172/jci.insight.98569.
View: Text | PDF
Research Article Endocrinology Metabolism

17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells

  • Text
  • PDF
Abstract

Clinical and experimental data indicate a beneficial effect of estrogens on energy and glucose homeostasis associated with improved insulin sensitivity and positive effects on insulin secretion. The aim of the study was to investigate the impact of estrogens on proglucagon-producing cells, pancreatic α cells, and enteroendocrine L cells. The consequences of sexual hormone deprivation were evaluated in ovariectomized mice (ovx). Ovx mice exhibited impaired glucose tolerance during oral glucose tolerance tests (OGTT), which was associated with decreased GLP-1 intestinal and pancreatic secretion and content, an effect that was reversed by estradiol (E2) treatment. Indeed, E2 increased oral glucose–induced GLP-1 secretion in vivo and GLP-1 secretion from primary culture of mouse and human α cells through the activation of all 3 estrogen receptors (ERs), whereas E2-induced GLP-1 secretion from mouse and human intestinal explants occurred only by ERβ activation. Underlying the implication of ERβ, its selective agonist WAY20070 was able to restore glucose tolerance in ovx mice at least partly through plasma GLP-1 increase. We conclude that E2 directly controls both α- and L cells to increase GLP-1 secretion, in addition to its effects on insulin and glucagon secretion, highlighting the potential beneficial role of the estrogenic pathway and, more particularly, of ERβ agonists to prevent type 2 diabetes.

Authors

Sandra Handgraaf, Rodolphe Dusaulcy, Florian Visentin, Jacques Philippe, Yvan Gosmain

×

Figure 9

Estradiol increases GLP-1 release from human α- and L cells in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Estradiol increases GLP-1 release from human α- and L cells in vitro.
GL...
GLP-1 (A) and glucagon (B) releases were quantified in supernatants relative to content of sorted human α cells (n = 4 experiments in each group). (C) Glucose-stimulated insulin secretion in Human isolated β cells (n = 4 in each group). (D) GLP-1 secretion of dissociated mixed cells from human small intestine (duodenum) (n = 3 experiments in each group). One-way ANOVA with the Dunnett’s multiple comparison post test. *P ≤ 0.05 for vehicle- vs. E2 agonist–treated cells.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts